Patients with metastatic cancer who are treated with an anti-programmed death therapy are at an increased risk for neurological complications. READ MORE
In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors are more effective and safer than conventional second-line treatment
Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year.
A systemic immune response, rather than a local response of a tumor, determines successful remission following cancer immunotherapy.
Research in Review
In a recent trial, researchers determined complete response rates in patients with aggressive B-cell lymphomas after treatment with new a CAR T-cell product.
Chimeric antigen receptor T-cells may elicit responses in solid cancers by inducing cancer cell death and the release of tumor antigens that could stimulate T-cell activity.
Pembrolizumab improves response to chimeric antigen receptor T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia.
Early activation of programmed cell death-1 in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer.